[Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone]
| Autor: | Nollet, Sylvain, Berger, Eric, Deconinck, Eric, Baldauf, Edouard, Rumbach, Lucien |
|---|---|
| Přispěvatelé: | Saas, Philippe, Service de Neurologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service d'hématologie, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service de neurologie, CH Colmar, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]) |
| Jazyk: | francouzština |
| Rok vydání: | 2006 |
| Předmět: |
MESH: Analgesics
MESH: Humans MESH: Middle Aged MESH: Leukemia MESH: Acute Disease MESH: Adult [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] MESH: Mitoxantrone MESH: Multiple Sclerosis MESH: Blood Cell Count MESH: Female |
| Zdroj: | Revue Neurologique Revue Neurologique, Elsevier Masson, 2006, 162 (2), pp.195-9 |
| ISSN: | 0035-3787 |
| Popis: | International audience; INTRODUCTION: Mitoxantrone (Mx) is used as a second-line treatment in multiple sclerosis. Since 1998, eight cases of acute leukemia (AL) have been described. We report two new cases of myeloid AL that occurred during treatment with Mx. OBSERVATIONS: The first case concerned a women who was treated with Mx for 3 months. In spite of a very low total dose (58.32 mg), she developed promyelocytic AL. The second patient died of myeloid AL, 27 months after the last injection of Mx. DISCUSSION: All the reported cases of AL occurring after Mx respond to the criteria of leukemia induced by anti-topoisomerases II. Epidemiological data and those from animal experiments suggest that Mx has direct role in the occurrence of leukemia. CONCLUSION: It must be remembered that even if the risk of Mx-induced leukemia is low, blood cell counts must be closely monitored for at least five years after the last injection of this treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect